Physician profile
Joseph Bailey
NPI 1720630031
$4,972.76
in general payments reported to CMS, 2019-2025
13 companies · $284 in 2025
The $284 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $275 · 2020: $423 · 2021: $861 · 2022: $2,562 · 2023: $454 · 2024: $113 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $830 · Entertainment: $21.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $829.60 |
| Entertainment | $21.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $2,910.05 | 2019-2023 | Acuvue |
| Coopervision INC. | $702.78 | 2021-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $574.53 | 2019-2021 | |
| Alcon Vision LLC | $259.43 | 2019-2024 | Dailies Total1, Dailies |
| Bausch & Lomb Americas INC. | $235.12 | 2022-2025 | Infuse |
| Allergan, INC. | $73.70 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $45.00 | 2024-2025 | Xdemvy |
| Abbvie INC. | $41.21 | 2022 | |
| Kala Pharmaceuticals, INC. | $37.40 | 2021 | |
| Optos, INC. | $35.52 | 2021-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Oyster Point Pharma, INC. | $24.54 | 2022 | |
| Visioneering Technologies, INC. | $18.05 | 2021 | |
| Thea Pharma INC. | $15.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.